NCT06041256 - A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 25, 2024

Study Completion Date

October 31, 2025

Conditions

Corneal EdemaCorneal Endothelial Dysfunction

Interventions

COMBINATION_PRODUCT

AURN001

Corneal Endothelial Cells and Y27632

Trial Locations (20)

11576

Aurion Biotech site, Garden City

19004

Aurion Biotech site, Bala-Cynwyd

23502

Aurion Biotech site, Norfolk

27157

Aurion Biotech site, Winston-Salem

30339

Aurion Biotech site, Atlanta

45242

Aurion Biotech site, Cincinnati

46260

Aurion Biotech site, Indianapolis

55305

Aurion Biotech site, Minnetonka

57108

Aurion Biotech site, Sioux Falls

67206

Aurion Biotech site, Wichita

72205

Aurion Biotech site, Little Rock

73104

Aurion Biotech site, Oklahoma City

77027

Aurion Biotech site, Houston

77055

Aurion Biotech site, Houston

90067

Aurion Biotech site, Los Angeles

94158

Aurion Biotech site, San Francisco

98125

Aurion Biotech site, Seattle

V5Z 1K1 CAN

Aurion Biotech site, Vancouver

L6H 0J8 CAN

Aurion Biotech site, Oakville

M5T 3A9 CAN

Aurion Biotech site, Toronto